Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
36. |
ECCT/22/10/05 |
Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
37. |
ECCT/22/10/03 | ISSC A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children… read more |
Principal Investigator(s) 1. Eunice Akinyi Ouma Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
View |
38. |
ECCT/22/10/02 |
Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Janet N Oyieko Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research… read more |
View |
39. |
ECCT/22/09/01 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.… read more |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Godfrey Allan Otieno Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2.… read more |
View |
40. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA… read more |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera … read more |
View |